Savara presented data at the european respiratory society (ers) international congress 2022

Austin, texas--(business wire)--savara inc. (nasdaq: svra), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented three posters at the ers international congress 2022 that took place september 4-6th in barcelona, spain. below are summaries of each poster presented: abstract #2170: “impala: efficacy measures in patients with autoimmune pulmonary alveolar proteinosis (apap) who required whole lung lavage” presented by y. inoue, m.d., ph.d. presented data from
SVRA Ratings Summary
SVRA Quant Ranking